Brent Del Monte, Co-Head of the Health and Life Sciences Practice and firm Principal, joined BGR in July, 2015. He helps clients formulate policies, and then works with them to achieve these policy priorities by developing strategies to best engage with Congress and the Administration, and then executing upon these strategies with, and on behalf of, clients.
Immediately prior to joining BGR, Brent served as the Vice President for Federal Government Relations at the Biotechnology Innovation Organization (BIO) for ten years. In this role, he was responsible for leading the efforts to accomplish BIO’s priorities on the Hill and within the Administration. Before accomplishing these objectives, Brent first had to achieve consensus on policy among BIO’s more than 1,000 member companies. During his time at BIO he helped the organization successfully engage with the Congress in the enactment of legislation creating a FDA biosimilars approval pathway and legislation allowing refundable tax credits for pre-profit biotechnology companies working on certain priority treatments.
Before joining BIO, Brent served as FDA Counsel at the Committee on Energy and Commerce under Rep. Tom Bliley (R-VA) and then Rep. Billy Tauzin (R-LA). During his time at the Committee, he successfully negotiated the reauthorization of the Prescription Drug User Fee Act, as well as the creation of Emergency Use Authorization authority and the Medical Device User Fee Act. Before that, Brent worked in the personal office of Rep. Bliley, where he served as his Legislative Director while attending Georgetown Law in the evening.
Areas of Focus
- Food and Drug administration
- Public Health
- Legislative and Regulatory policy development
Education
-
College of William & Mary
B.A., Government -
Georgetown University Law School
J.D., Magnum Cum Laude